Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | PTGIR | P43119 | 10/20 | 0.58 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mexiprostil SCHEMBL10920583 | 1.00 | LMNA (0.68) | LMNAABCC4PGRALDH1A1POLB | |
| Mexiprostil SCHEMBL15153215 | 1.00 | LMNA (0.68) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL15164656 | 0.95 | LMNA (0.64) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL9651264 | 0.92 | PTGIR (0.67) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL10589368 | 0.92 | PTGIR (0.67) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL10589373 | 0.92 | PTGIR (0.67) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL9781655 | 0.92 | PTGIR (0.67) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL11300441 | 0.84 | LMNA (0.61) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL2954688 | 0.83 | PTGIR (0.79) | LMNAABCC4PGRALDH1A1POLB | |
| SCHEMBL29356252 | 0.83 | PTGIR (0.79) | LMNAABCC4PGRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629778-B1 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME | COSMO TECHNOLOGIES LTD (IE) | 2016-09-21 | — | — | EP | claimed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2629778-A1 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME | Cosmo Technologies Ltd. (IE) | 2013-08-28 | — | — | EP | claimed |
| US-20130202704-A1 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME | COSMO TECHNOLOGIES LTD. (IE) | 2013-08-08 | — | — | US | claimed |
| CN-103167874-A | Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome | COSMO TECHNOLOGIES LTD | 2013-06-19 | — | — | CN | claimed |
| WO-2012052918-A1 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME | COSMO TECHNOLOGIES LTD. (IE) | 2012-04-26 | — | — | WO | claimed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | claimed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | claimed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | claimed |
| EP-2007705-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2007126609-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-7176238-B1 | Nitrostated and nitrosylated prostaglandins, compositions and methods of use | NITROMED INC. (US) | 2007-02-13 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2000051978-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METODS OF USE | NITROMED, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-20220289787-A1 | DIMER COMBINATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-09-15 | — | — | US | disclosed |
| EP-4003362-A1 | ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS | Ripple Therapeutics Corporation (CA) | 2022-06-01 | — | — | EP | disclosed |
| EP-0853481-A1 | COMPOSITIONS FOR TREATING INFLAMMATION CONTAINING CERTAIN PROSTAGLANDINS AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | MERCK FROSST CANADA INC. (CA) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997011701-A1 | COMPOSITIONS FOR TREATING INFLAMMATION CONTAINING CERTAIN PROSTAGLANDINS AND A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | MERCK-FROSST CANADA INC. (CA) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289787-A1 | DIMER COMBINATIONS AND USES THEREOF | SHBG, SERPINA6, FKBP2 | LMNA 2991/4885ABCC4 3311/4885PGR 27/4885 |
| US-20130202704-A1 | USE OF MEXIPROSTIL IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND/OR OF IRRITABLE BOWEL SYNDROME | VIPR2, SLC10A2, FABP2 | LMNA 4093/4885ABCC4 980/4885PGR 3569/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | LMNA 2819/4885ABCC4 4339/4885PGR 140/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | LMNA 2873/4885ABCC4 3014/4885PGR 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.